Abstract
Social media and health-related forums, including the expression of customer reviews, have recently provided data sources for adverse drug reaction (ADR) identification research. However, in the existing methods, the neglect of noise data and the need for manually labeled data reduce the accuracy of the prediction results and greatly increase manual labor. We propose a novel architecture named the weakly supervised mechanism (WSM) convolutional neural network (CNN) long-short-term memory (WSM-CNN-LSTM), which combines the strength of CNN and bi-directional long short-term memory (Bi-LSTM). The WSM applies the weakly labeled data to pre-train the parameters of the model and then uses the labeled data to fine-tune the initialized network parameters. The CNN employs a convolutional layer to study the characteristics of the drug reviews and active features at different scales, and then the feed-forward and feed-back neural networks of the Bi-LSTM utilize these salient features to output the regression results. The experimental results effectively demonstrate that our model marginally outperforms the comparison models in ADR identification and that a small quantity of labeled samples results in an optimal performance, which decreases the influence of noise and reduces the manual data-labeling requirements.
Highlights
Adverse drug reactions (ADRs) are part of the leading cause of morbidity and mortality in public health
We propose a model that applies the weakly supervised mechanism (WSM) combining the strength of the convolutional neural network (CNN) and bi-directional long-short-term memory (Bi-LSTM) [23,24,25] to complete the sentiment classification task of ADR reviews
Our contributions are as follows: We propose a novel method that uses a WSM for the sentiment analysis of ADR reviews to avoid a large amount of manually labeled data
Summary
Adverse drug reactions (ADRs) are part of the leading cause of morbidity and mortality in public health. Research has indicated that death and hospitalizations due to ADRs number in the millions (up to 5% hospitalizations, 28% emergency treatments, and 5% death), and the related consumption is approximately 75 billion dollars annually [1,2,3]. Post-marketing drug safety monitoring is essential for pharmacovigilance. Regulatory agencies (e.g., the Food and Drug Administration (FDA)) establish and support spontaneous reporting systems (SRS) to monitor the most current pharmacovigilance activities in the United States. Suspected ADRs may be raised by patients and healthcare providers through these surveillance systems. Biased and underreported events limit the effectiveness of these systems, which report an estimated ADR rate of approximately 10% [4]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.